Charlotte F

30 publications in the catalogue · 2001–2025

30 publications

Diseases

  1. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025

    FibroTest-T2D Metabolic

  2. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  3. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019

    FibroTest LCR1 LCR2 Alcohol +3

  4. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019

    LCR1 LCR2 Alcohol HBV +4

  5. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019

    NashTest-2 SteatoTest-2 Metabolic

  6. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    FibroTest NashTest SteatoTest Metabolic

  7. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018

    ActiTest FibroTest NashTest NashTest-2 +3

  8. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018

    FibroTest Alcohol HBV HCV +1

  9. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016

    ActiTest FibroTest SteatoTest Metabolic

  10. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015

    AshTest Alcohol

  11. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013

    FibroTest HCV

  12. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012

    FibroTest Alcohol HBV HCV +3

  13. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012

    ActiTest FibroTest NashTest SteatoTest +1

  14. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012

    Elasto-FibroTest FibroTest HCV

  15. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012

    FibroTest HCV

  16. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008

    ActiTest FibroTest HCV

  17. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007

    FibroTest Alcohol HBV HCV +1

  18. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007

    FibroTest HCV

  19. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication

    Ngo Y et al. · Clin Chem · 2006

    FibroTest HCV

  20. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006

    ActiTest FibroTest HCV

  21. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006

    FibroTest Metabolic

  22. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006

    NashTest Metabolic

  23. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006

    AshTest Alcohol

  24. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005

    SteatoTest Alcohol HBV HCV +1

  25. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004

    ActiTest FibroTest HCV

  26. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003

    FibroTest HCV

  27. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003

    ActiTest FibroTest HBV

  28. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003

    FibroTest HCV HIV

  29. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

    Myers RP et al. · Am J Gastroenterol · 2002

    FibroTest HCV

  30. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001

    FibroTest HCV